Celldex Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

• Celldex Therapeutics, Inc. showed an increase of +1.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from Celldex Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
• XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2011: $10.14 million | Q2 2011: $10.83 million | Q3 2011: $13.10 million | Q1 2012: $22.76 million | Q2 2012: $18.56 million | Q3 2012: $23.19 million | Q1 2013: $75.63 million | Q2 2013: $25.90 million | Q3 2013: $14.63 million | Q1 2014: $56.90 million | Q2 2014: $40.80 million | Q3 2014: $32.53 million | Q1 2015: $122.17 million | Q2 2015: $81.58 million | Q3 2015: $66.79 million | Q1 2016: $63.03 million | Q2 2016: $32.48 million | Q3 2016: $31.74 million | Q1 2017: $42.50 million | Q2 2017: $66.16 million | Q3 2017: $54.74 million | Q1 2018: $39.82 million | Q2 2018: $43.89 million | Q3 2018: $32.82 million | Q1 2019: $31.53 million | Q2 2019: $19.74 million | Q3 2019: $16.59 million | Q4 2019: $11.23 million | Q1 2020: $22.72 million | Q2 2020: $68.03 million | Q3 2020: $18.15 million | Q1 2021: $69.31 million | Q2 2021: $43.45 million | Q3 2021: $72.18 million | Q1 2022: $25.29 million | Q2 2022: $28.40 million | Q3 2022: $18.58 million | Q1 2023: $54.12 million | Q2 2023: $28.22 million | Q3 2023: $21.13 million | Q1 2024: $115.08 million | Q2 2024: $42.74 million | Q3 2024: $36.40 million | Q1 2025: $17.14 million | Q2 2025: $23.04 million | Q3 2025: $36.04 million.
• Over the full 18 years of available data (2008 to 2025), Celldex Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 34.8%.
• Historical annual values: Fiscal year 2025: $28.87 million | Fiscal year 2024: $28.36 million | Fiscal year 2023: $34.81 million | Fiscal year 2022: $29.43 million | Fiscal year 2021: $39.14 million | Fiscal year 2020: $43.84 million | Fiscal year 2019: $11.23 million | Fiscal year 2018: $24.31 million | Fiscal year 2017: $40.29 million | Fiscal year 2016: $42.46 million | Fiscal year 2015: $72.11 million | Fiscal year 2014: $28.02 million | Fiscal year 2013: $169.40 million | Fiscal year 2012: $24.90 million | Fiscal year 2011: $11.90 million | Fiscal year 2010: $21.29 million | Fiscal year 2009: $57.00 million | Fiscal year 2008: $44.26 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026